1. Home
  2. BBIO vs LII Comparison

BBIO vs LII Comparison

Compare BBIO & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$69.63

Market Cap

14.2B

Sector

Health Care

ML Signal

HOLD

Logo Lennox International Inc.

LII

Lennox International Inc.

HOLD

Current Price

$495.50

Market Cap

15.8B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBIO
LII
Founded
2015
1895
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
14.2B
15.8B
IPO Year
2019
1999

Fundamental Metrics

Financial Performance
Metric
BBIO
LII
Price
$69.63
$495.50
Analyst Decision
Strong Buy
Hold
Analyst Count
25
13
Target Price
$86.04
$566.58
AVG Volume (30 Days)
1.7M
423.9K
Earning Date
04-29-2026
04-29-2026
Dividend Yield
N/A
1.03%
EPS Growth
N/A
1.11
EPS
N/A
22.79
Revenue
$502,076,000.00
$5,195,300,000.00
Revenue This Year
$89.45
$6.85
Revenue Next Year
$73.78
$5.76
P/E Ratio
N/A
$22.10
Revenue Growth
126.26
N/A
52 Week Low
$31.77
$434.06
52 Week High
$84.94
$689.44

Technical Indicators

Market Signals
Indicator
BBIO
LII
Relative Strength Index (RSI) 40.40 53.10
Support Level $61.95 $479.34
Resistance Level $78.96 $498.78
Average True Range (ATR) 4.00 17.34
MACD -0.72 2.46
Stochastic Oscillator 2.54 51.86

Price Performance

Historical Comparison
BBIO
LII

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About LII Lennox International Inc.

Lennox International manufacturers and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounted for 67% of sales and commercial HVAC (building climate solutions) accounted for the remaining 33% of sales. To be clear, Lennox's commercial exposure is what its peers refer to as "residential and light commercial," lacks the scale and complexity of what is referred to as an "applied" solution. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand.

Share on Social Networks: